PTC Therapeutics Secures Global Approvals for Sephience in PKU Treatment Across Canada and Japan
Key Insights
PTC Therapeutics received Health Canada approval for Sephience (sepiapterin) to treat hyperphenylalaninemia (search) in PKU patients aged one month and older, with the drug now commercially available in Canada.
The Japanese Ministry of Health, Labor and Welfare (search) approved Sephience for PKU treatment across all ages and disease severity spectrum, marking PTC's first product approval in Japan.
Sephience acts as a natural precursor to BH4 (search), a critical co-factor for phenylalanine hydroxylase (search), enabling effective reduction of blood phenylalanine levels in PKU patients.
PTC Therapeutics has achieved significant regulatory milestones with the approval of Sephience (sepiapterin) for phenylketonuria (search) (PKU) treatment in both Canada and Japan, expanding global access to this novel therapy for a rare metabolic disorder affecting an estimated 58,000 people worldwide.
Health Canada Grants Broad Approval
Health Canada has approved Sephience for the treatment of hyperphenylalaninemia (search) (HPA) in adult and pediatric patients one month old and older with sepiapterin-responsive phenylketonuria (search). The drug is now commercially available in Canada, providing a new treatment option for patients who must maintain strict phenylalanine-restricted diets.
"We're pleased with the Canadian regulatory approval of Sephience and opportunity to provide access to this important therapy to children and adults living with phenylketonuria (search) in Canada," said Matthew B. Klein, MD, chief executive officer of PTC Therapeutics. "There is a significant unmet medical need for new therapies that address a broad spectrum of phenylketonuria subtypes."
The Health Canada approval is based on evidence of significant efficacy and safety from the phase 3 APHENITY trial as well as durability of treatment effect in the APHENITY long-term extension study.
Japan Approval Marks Company Milestone
In a separate regulatory achievement, the Japanese Ministry of Health, Labor and Welfare (search) (MHLW) approved Sephience for PKU treatment in children and adults, with the label including individuals of all ages and the full spectrum of disease severity. This represents PTC Therapeutics' first product approval in Japan.
"The approval of Sephience in Japan is an important milestone for Japanese patients living with PKU as well as for PTC," said Klein. "I am proud that we have been able to achieve approvals for Sephience in the EU, US and Japan within less than six months, allowing for a true global launch. Our team in Japan is fully built and excited to bring Sephience to any individual who may benefit."
PTC will now engage in pricing discussions in Japan, which are expected to conclude in Q1 2026, with launch occurring shortly thereafter.
Mechanism of Action and Clinical Significance
Sephience is a natural precursor of the enzymatic co-factor BH4 (search), a critical co-factor for phenylalanine hydroxylase (search) (PAH). Through its mechanism of action, Sephience effectively reduces blood phenylalanine (Phe) levels and has the potential to treat a broad range of PKU patients. The drug is indicated in conjunction with a phenylalanine-restricted diet.
"There continues to be a significant unmet need for new treatment options in phenylketonuria (search) which can support improved dietary flexibility and management, a meaningful goal for those living with phenylketonuria in Canada and around the world," said Tanya Chute Nagy, chief executive officer and president of Canadian PKU and Allied Disorders.
Understanding Phenylketonuria
Phenylketonuria (search) is a rare, inherited metabolic disease characterized by the body's inability to break down phenylalanine, an essential amino acid. If left untreated or poorly managed, phenylalanine can build up to harmful levels, causing severe and irreversible disabilities including permanent intellectual disability, seizures, delayed development, memory loss, and behavioral and emotional problems.
Newborns with PKU initially show no symptoms, but the condition is progressive, and damage from toxic phenylalanine levels in early life is irreversible. Diagnosis typically occurs through newborn screening programs, emphasizing the importance of early intervention.
Global Regulatory Success
With these latest approvals, Sephience is now approved in the European Economic Area, the United States, Canada, and Japan, representing a comprehensive global regulatory achievement for PTC Therapeutics. The rapid succession of approvals across major markets demonstrates the significant clinical need and regulatory recognition of the drug's therapeutic value in PKU management.